TD Cowen analyst Joseph Thome has maintained their bullish stance on VRDN stock, giving a Buy rating today.
Joseph Thome has given his Buy rating due to a combination of factors including Viridian Therapeutics’ strong performance in their TED trials and promising pipeline developments. The company’s veligrotug program has successfully met all primary and secondary endpoints in both active and chronic TED trials, suggesting a differentiated profile that could compete favorably against existing treatments like Tepezza. This success supports the anticipated BLA submission in the second half of the year, with a potential U.S. launch expected in the latter half of 2026.
Additionally, Viridian is advancing its FcRn franchise with promising developments such as VRDN-006 and VRDN-008. The company plans to present proof-of-concept data for VRDN-006 in the third quarter, and further preclinical data for VRDN-008 is expected in 2025. These advancements, along with a solid cash position, underpin Thome’s confidence in the company’s growth trajectory and potential market impact, leading to his Buy rating.
In another report released today, Wedbush also maintained a Buy rating on the stock with a $46.00 price target.